CJC-1295 DAC

What Is CJC-1295 DAC?

CJC-1295 DAC is a long-acting synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) fitted with a Drug Affinity Complex (DAC) that binds circulating albumin, greatly extending its half-life. Where the “no-DAC” version acts briefly to mimic a natural GH pulse, the DAC version produces a sustained elevation of GH and IGF-1 — a so-called “GH bleed” rather than a pulse. It is sold as a research chemical and used off-label for body composition and recovery. It is not an approved dietary supplement or medicine.

Evidence

There is real, verifiable human pharmacology here: in randomised, placebo-controlled ascending-dose trials in healthy adults, a single subcutaneous injection of CJC-1295 DAC increased mean GH several-fold for roughly six days and IGF-1 for around nine to eleven days, with weekly/biweekly dosing sustaining the elevation ^{1Reference 1Teichman SL et al. · 2006RCTProlonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — randomised, placebo-controlledView study →}. These are pharmacodynamic/safety trials in healthy volunteers rather than clinical-outcome studies, so downstream claims about muscle gain, fat loss or anti-ageing benefit in humans are not established by those trials and should be treated as uncited. Note also that non-physiological, continuously elevated GH/IGF-1 is a mechanistic safety concern, not a demonstrated benefit.

Dosage & Safety

CJC-1295 DAC is a research peptide — not an approved dietary supplement or drug for human therapeutic use — and this entry is informational only. The controlled trials used single or weekly/biweekly subcutaneous doses under supervision ^{1Reference 1Teichman SL et al. · 2006RCTProlonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — randomised, placebo-controlledView study →}; that is a description of the studies, not a personal recommendation, and community dosing figures are not validated. Sustained supraphysiological GH/IGF-1 raises theoretical concerns around insulin resistance, fluid retention, carpal-tunnel-type symptoms and tissue overgrowth; formal human interaction, contraindication, pregnancy and long-term-safety data are not established / not assessed in this pass. Toxicity is not yet characterised from a citable long-term human basis.

References

1. Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — randomised, placebo-controlled. J Clin Endocrinol Metab. https://pubmed.ncbi.nlm.nih.gov/16352683/